This results in stabilization of PTEN and inhibition of proliferation by downstream AKT signaling. Overall scientific evidence shows that in melanoma, indole-3-carbinol specifically inhibits the two most commonly associated driver mutation signaling pathways to cause proliferation, a fact that can be used to design clinical trial to treat human patients with indole-3-carbinol in future.
The outcome of this process is the stabilization of PTEN and the inhibition of cell division by AKT signaling. In summary, scientific research shows that in melanoma, indole-3-carbinol specifically blocks the two most common driver mutation pathways that lead to proliferation, providing a basis for designing clinical trials to treat patients with indole-3-carbinol in the future.